IMCAS website has a fresh new look! Explore our redesigned website. We're here to help you navigate the new features and welcome your feedback at contact@imcas.com.
English
Español
Français
Português
Русский
简体中文
08:08
Bruxism and neurotoxins: an epidemic causing premature aging of the lower face and a multitude of medical ailments
08:24
Outcomes of the first-in-human study with a recombinant botulinum toxin E (rBoNT-E): safety and pharmacodynamic profile of rBoNT-E compared with abobotulinumtoxinA
08:32
Dosing of abobotulinumtoxinA for long-term treatment of glabellar lines: injection practices from the APPEAL non-interventional study
08:40
High subject satisfaction after aesthetic treatment of glabellar lines with abobotulinumtoxinA in up to three injection cycles
08:48
Safety, tolerability, and efficacy of repeat-dose injections of incobotulinum toxin / type A in the treatment of upper facial lines